The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
Abstract
An antibody-drug conjugate targeting LGR5 effectively treats intestinal cancer in preclinical models.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, LGR5-targeted antibody–drug conjugates were demonstrated to induce cytotoxicity in LGR5-high gastrointestinal cancer cells and decrease tumor size and proliferation in colon cancer xenograft models [181,182].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [181]
Citations
Cites
Identification of stem cells in small intestine and colon by marker gene Lgr5
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., et al. (2007) · Nature · doi:10.1038/nature06196 · Cited by 5,687 · cited 3×
“These findings support previously published work indicating that Lgr5 cells continuously contribute to an established tumor mass in the setting of the Apc mutation (4, 5).”
BackgroundResultInfluentialaffy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
Crypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
A Dominant Mutation That Predisposes to Multiple Intestinal Neoplasia in the Mouse
Moser, A. R., Pitot, H. C., & Dove, W. F. (1990) · Science · doi:10.1126/science.2296722 · Cited by 1,591 · cited 2×
“To enable such a model, we combined the APCmin model of intestinal tumorigenesis with conditional mutant KrasG12D expression under the control of the intestinal specific VillinCre (7, 19, 20).”
MethodIn vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
Huch, M., Dorrell, C., Boj, S. F., van Es, J. H., Li, V. S. W., van de Wetering, M., Sato, T., Hamer, K., Sasaki, N., Finegold, M. J., et al. (2013) · Nature · doi:10.1038/nature11826 · Cited by 1,555
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Self-citationA reserve stem cell population in small intestine renders Lgr5-positive cells dispensable
Tian, H., Biehs, B., Warming, S., Leong, K. G., Rangell, L., Klein, O. D., & de Sauvage, F. J. (2011) · Nature · doi:10.1038/nature10408 · Cited by 1,204
Cancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171
Cited by
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Intra-tumor heterogeneity from a cancer stem cell perspective
Prasetyanti, P. R., & Medema, J. P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0600-4 · Cited by 800
A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer
de Sousa e Melo, F., Kurtova, A. V., Harnoss, J. M., Kljavin, N., Hoeck, J. D., Hung, J., Anderson, J. E., Storm, E. E., Modrusan, Z., Koeppen, H., et al. (2017) · Nature · doi:10.1038/nature21713 · Cited by 788
Visualization and targeting of LGR5+ human colon cancer stem cells
Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., Date, S., Sugimoto, S., Kanai, T., & Sato, T. (2017) · Nature · doi:10.1038/nature22081 · Cited by 728
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Engineering protein-based therapeutics through structural and chemical design
Ebrahimi, S. B., & Samanta, D. (2023) · Nature Communications · doi:10.1038/s41467-023-38039-x · Cited by 382
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Determinants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 258
“As recently shown, antibodies targeting Lgr5 coupled to different toxins demonstrated potent anti-tumour efficacy in preclinical models of CRC (Junttila et al., 2015) (Figure 3).”
BackgroundPayload diversification: a key step in the development of antibody–drug conjugates
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01397-y · Cited by 257
“Payloads that are substrates for efflux pumps have been found to be limiting factors in ADC development [111].”
BackgroundKatoh, M. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3689 · Cited by 211
“As transmembrane proteins expressed on tumor cells are appropriate targets for the development of peptide-based drugs (142), mAbs, antibody‑drug conjugates (ADCs), bi‑specific antibodies (bsAbs) and chimeric antigen receptor‑modified T cells (150-155), drugs targeting cd44v6, FZd7 and LGR5 are under development as fun…”
Wnt Signaling in Cancer Stem Cell Biology
De Sousa e Melo, F., & Vermeulen, L. (2016) · Cancers · doi:10.3390/cancers8070060 · Cited by 236
“Lgr5 Colon, Gastric [34,35,44] CD24 Pancreas, Colon [45] Prom1 Colon, Brain, Pancreas [46–49] CD44 Colon, Breast, Liver, Pancreas, Prostate [36,37,50–52] ALDH1 Colon, Breast [53,54]”
BackgroundRoberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Hutchings, C. J., Koglin, M., Olson, W. C., & Marshall, F. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.91 · Cited by 198
Cellular Plasticity in Intestinal Homeostasis and Disease
de Sousa e Melo, F., & de Sauvage, F. J. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.019 · Cited by 181
Damelin, M., Bankovich, A., Bernstein, J., Lucas, J., Chen, L., Williams, S., Park, A., Aguilar, J., Ernstoff, E., Charati, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2611 · Cited by 163
“ADCs that effectively and specifically target TICs should offer a therapeutic advantage by limiting the opportunity for acquired resistance and by sparing normal tissues from damage (8, 11, 12).”
BackgroundRecent Advances in Lgr5 + Stem Cell Research
Leung, C., Tan, S. H., & Barker, N. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.01.010 · Cited by 161
Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?
Morgan, R., Mortensson, E., & Williams, A. C. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0118-6 · Cited by 153
“With this in mind, a thorough assessment of the long-term treatment-associated toxicity of LGR5 targeting is critical given the importance of LGR5 to normal colonic stem cell biology, and the previously reported side effects (severe gut and liver toxicity) of such strategies.(61,87) Finally, if pharmacological targeti…”
BackgroundD’Amico, L., Menzel, U., Prummer, M., Müller, P., Buchi, M., Kashyap, A. S., Haessler, U., Yermanos, A., Gébleux, R., Briendl, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0464-1 · Cited by 140
LncGata6 maintains stemness of intestinal stem cells and promotes intestinal tumorigenesis
Zhu, P., Wu, J., Wang, Y., Zhu, X., Lu, T., Liu, B., He, L., Ye, B., Wang, S., Meng, S., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0194-0 · Cited by 134
LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0114 · Cited by 130
“In fact, while this manuscript was in preparation, a report was published further validating the importance and effectiveness of targeting LGR5 for the treatment of colon cancer using different ADCs (44).”
BackgroundInsel, P. A., Sriram, K., Wiley, S. Z., Wilderman, A. S., Katakia, T., McCann, T., Yokouchi, H., Zhang, L., Corriden, R., Liu, D., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00431 · Cited by 139
“(Junttila et al., 2015; Lelle et al., 2015; Gong et al., 2016; Gilabert-Oriol et al., 2017).”
Antibody–Drug Conjugates for Cancer Therapy
Parslow, A. C., Parakh, S., Lee, F.-T., Gan, H. K., & Scott, A. M. (2016) · Biomedicines · doi:10.3390/biomedicines4030014 · Cited by 120
“The importance of payload selection for stem cell targeting was recently reported in the analysis of two ADCs targeting the Lgr5+ colorectal stem cell and putative cancer stem cell marker [44].”
BackgroundXu, L., Lin, W., Wen, L., & Li, G. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1288-8 · Cited by 125
Frank, M. H., Wilson, B. J., Gold, J. S., & Frank, N. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.080 · Cited by 105
Hagerling, C., Owyong, M., Sitarama, V., Wang, C., Lin, C., van den Bijgaart, R. J. E., Koopman, C. D., Brenot, A., Nanjaraj, A., Wärnberg, F., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06986-z · Cited by 93
“Once tumors reached 150–200mm(3), we treated the mice with anti-LGR5 (hu8E11v2)-MC-vc-PABMMAE, a well-characterized antibody-drug conjugate (ADC) targeting LGR5 with minimal side-effects in mice such as minor weight loss [56].”
Reprogramming of central carbon metabolism in cancer stem cells
Wong, T. L., Che, N., & Ma, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.05.012 · Cited by 88
“showed that targeting LGR5+ cells with an antibody-drug conjugate (ADC) can decrease tumor size and prolong survival in xenografts [48].”
BackgroundSahara, M., Santoro, F., Sohlmér, J., Zhou, C., Witman, N., Leung, C. Y., Mononen, M., Bylund, K., Gruber, P. J., & Chien, K. R. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.01.005 · Cited by 88
Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer
Mzoughi, S., Schwarz, M. C., Wang, X., Demircioğlu, D., Ulukaya, G. B., Mohammed, K., Zorgati, H., Torre, D., Tomalin, L. E., Tullio, F. D., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02058-1 · Cited by 102
Self-citationModulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
Su, D., Kozak, K. R., Sadowsky, J., Yu, S., Fourie-O’Donohue, A., Nelson, C., VANDLEN, R. L., Ohri, R. V., Liu, L., Ng, C., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00785 · Cited by 89
Self-citationStefan, N., Gébleux, R., Waldmeier, L., Hell, T., Escher, M., Wolter, F. I., Grawunder, U., & Beerli, R. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0688 · Cited by 82
“31), as well as novel anthracylines (32, 33).”
BackgroundLGR5 marks targetable tumor-initiating cells in mouse liver cancer
Cao, W., Li, M., Liu, J., Zhang, S., Noordam, L., Verstegen, M. M. A., Wang, L., Ma, B., Li, S., Wang, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15846-0 · Cited by 86
Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation
Nilchan, N., Li, X., Pedzisa, L., Nanna, A. R., Roush, W. R., & Rader, C. M. (2019) · Antibody Therapeutics · doi:10.1093/abt/tbz009 · Cited by 93
Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
Masoumi, J., Jafarzadeh, A., Abdolalizadeh, J., Khan, H. Z., Jeandet, P., Mirzaei, H., & Mirzaei, H. R. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.015 · Cited by 90
Mechanisms of angiogenesis in tumour
Zhang, R., Yao, Y., Gao, H., & Hu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1359069 · Cited by 109
Stem cell plasticity enables hair regeneration following Lgr5+ cell loss
Hoeck, J. D., Biehs, B., Kurtova, A. V., Kljavin, N. M., Melo, F. D. S. E., Alicke, B., Koeppen, H., Modrusan, Z. D., Piskol, R., & de Sauvage, F. J. (2017) · Nature Cell Biology · doi:10.1038/ncb3535 · Cited by 82
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“For example, LGR5-targeted antibody–drug conjugates were demonstrated to induce cytotoxicity in LGR5-high gastrointestinal cancer cells and decrease tumor size and proliferation in colon cancer xenograft models [181,182].”
Moore, P. A., Shah, K., Yang, Y., Alderson, R. F., Roberts, P., Long, V., Liu, D., Li, J. C., Burke, S., Ciccarone, V. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1086 · Cited by 79
Poli, V., Fagnocchi, L., & Zippo, A. (2018) · Stem Cells International · doi:10.1155/2018/4598195 · Cited by 83
“To this purpose, experiments performed in xenograft and in genetically engineered mouse models of intestinal tumorigenesis succeeded in eliminating LGR5 CSCs, demonstrating potent antitumor efficacy [149, 150].”
MethodStem cells in homeostasis and cancer of the gut
van der Heijden, M., & Vermeulen, L. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0962-x · Cited by 84
“In xenograft studies it was shown that specifically targeting the Lgr5 cells through antibody-drug conjugated therapy, or directly genetically, indeed inhibits tumor growth without affecting intestinal epithelium homeostasis [4, 136, 137].”
BackgroundTargeting stemness of cancer stem cells to fight colorectal cancers
Du, L., Cheng, Q., Zheng, H., Liu, J., Liu, L., & Chen, Q. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.012 · Cited by 76
Khera, E., & Thurber, G. M. (2018) · BioDrugs · doi:10.1007/s40259-018-0302-5 · Cited by 80
Identification, isolation and characterization of human LGR5-positive colon adenoma cells
Dame, M. K., Attili, D., McClintock, S. D., Dedhia, P. H., Ouillette, P. D., Hardt, O., Chin, A. M., Xue, X., Laliberté, J., Katz, E. L., et al. (2018) · Development · doi:10.1242/dev.153049 · Cited by 74
“Recently antibody drug conjugates (ADCs) have been developed to target cells expressing LGR5, demonstrating therapeutic potential (Gong et al., 2016, Junttila et al., 2015), but as part of these applications primary human cell isolation and characterization was limited (Hirsch and Ried, 2016).”
BackgroundInfluentialKim, M. S., Cho, H. I., Yoon, H. J., Ahn, Y.-H., Park, E. J., Jin, Y. H., & Jang, Y. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-24903-0 · Cited by 71
WNT and β-Catenin in Cancer: Genes and Therapy
Jackstadt, R., Hodder, M. C., & Sansom, O. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033628 · Cited by 78
“Efforts are underway to target LGR5+ cells with antibody-drug conjugates, with some success in preclinical models (Gong et al. 2016, Junttila et al. 2015).”
BackgroundNatural Product Splicing Inhibitors: A New Class of Antibody–Drug Conjugate (ADC) Payloads
Puthenveetil, S., Loganzo, F., He, H., DiRico, K. J., Green, M., Teske, J. A., Musto, S., Clark, T. H., Rago, B., Koehn, F. E., et al. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00291 · Cited by 67
Lineage tracing and targeting of IL17RB + tuft cell-like human colorectal cancer stem cells
Goto, N., Fukuda, A., Yamaga, Y., Yoshikawa, T., Maruno, T., Maekawa, H., Inamoto, S., Kawada, K., Sakai, Y., Miyoshi, H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1900251116 · Cited by 63
“From these results, it should be possible to target IL17RB CSCs for antibody therapeutics by employing antibody– drug conjugates, similar to previous reports that show targeting of LGR5 cells (40), rather than blocking the receptor signal.”
Application of Immuno-PET in Antibody–Drug Conjugate Development
Carmon, K. S., & Azhdarinia, A. (2018) · Molecular Imaging · doi:10.1177/1536012118801223 · Cited by 64
“ADCs are also being developed to target tumor microenvironment proteins such as transmembrane 4 L6 family member 1(15) and cancer stem cell targets including leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5).(16,17) Interestingly, ADC technology is also being evaluated for nononcologic indications inc…”
BackgroundEngel, R. M., Chan, W. H., Nickless, D. K., Hlavca, S., Richards, E., Kerr, G., Oliva, K., McMurrick, P. J., Jardé, T., & Abud, H. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010128 · Cited by 64
Becerril-Rico, J., Alvarado-Ortiz, E., Toledo-Guzmán, M. E., Pelayo, R., & Ortíz-Sánchez, E. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02562-9 · Cited by 66
Logarithmic expansion of LGR5 + cells in human colorectal cancer
Martín, M. L., Zeng, Z., Adileh, M., Jacobo, A., Li, C., Vakiani, E., Hua, G., Zhang, L., Haimovitz‐Friedman, A., FUKS, Z. Y., et al. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.09.018 · Cited by 61
Third-Generation Antibody Drug Conjugates for Cancer Therapy–A Balancing Act
Vankemmelbeke, M. N., & Durrant, L. G. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0002 · Cited by 58
A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Park, W.-J., & Kim, M. J. (2023) · Cells · doi:10.3390/cells12081110 · Cited by 57
Wang, Y., Lu, K., Yang, X., Xu, S., Chu, H., & Fang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1678907 · Cited by 69
Zhang, S., Chatterjee, T., Godoy, C., Wu, L., Liu, Q. J., & Carmon, K. S. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0436 · Cited by 55
“However, a fraction of the tumors eventually recurred subsequent to treatment termination, likely due to LGR5 downregulation or resistance to MMAE (8, 9).”
BackgroundLiu, X., Lin, X.-K., Mei, Y., Ahmad, S., Yan, C., Jin, H., Yu, H. J., Chen, C., Lin, C., & Yu, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01741 · Cited by 53
Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy
Yu, S., Xiao, H., Ma, L., Zhang, J., & Zhang, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188946 · Cited by 53
Self-citationSphyris, N., Hodder, M. C., & Sansom, O. J. (2021) · Cancers · doi:10.3390/cancers13051000 · Cited by 52
“Moreover, the fact that Lgr5− differentiated tumour cells must re-express Lgr5 in order to repopulate the CSC pool, following its depletion during treatment [297], or to colonize the distant site [302] holds promise for ongoing efforts to develop LGR5 antibody-drug conjugates [293,355,389].”
BackgroundImmune Curbing of Cancer Stem Cells by CTLs Directed to NANOG
Wefers, C., Schreibelt, G., Massuger, L. F. A. G., de Vries, I. J. M., & Torensma, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01412 · Cited by 47
Plasticity of differentiated cells in wound repair and tumorigenesis, part II: skin and intestine
Burclaff, J., & Mills, J. C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035071 · Cited by 48
“Even continued ablation of Lgr5Hi cells in existing tumors using targeted antibody-drug conjugates resulted only in smaller tumors and longer animal survival, but not full recovery (Junttila et al., 2015).”
BackgroundTao, Y., Wang, R., Lai, Q., Wu, M., Wang, Y., Jiang, X., Zeng, L., Zhou, S., Li, Z., Yang, T., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12520 · Cited by 47
“Additionally, other ADC target Lgr5 (Junttila et al., 2015), Sialyl-Thomsen-nouveau antigen (Prendergast et al., 2017), RON RTK (Feng et al., 2014) and 5T4 oncotrophoblast glycoprotein (Wang et al., 2018) have been under development for CRC treatment.”
BackgroundZhao, Q., Zong, H., Zhu, P., Su, C., Tang, W., Chen, Z., & Jin, S. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00474-x · Cited by 50
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
White, M., Mills, M. L., Millett, L. M., Gilroy, K. L., Hong, Y., Zeiger, L. B., Simpson, R. J., Corry, S. M., Ligeza, A., Lannagan, T. R. M., et al. (2025) · Nature · doi:10.1038/s41586-025-09916-w · Cited by 53
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges
O’Brien, S., Chidiac, R., & Angers, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.03.008 · Cited by 45
He, J., Li, W., Wang, S., Jin, L., Hong, X., Liao, L., Kang, D., Wang, W., Wang, R., Zhang, W., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217917 · Cited by 55
Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
Kim, M. J., Huang, Y., & Park, J. (2020) · Cancers · doi:10.3390/cancers12123638 · Cited by 43
“Since RSPOs and LGRs are differently expressed in different tissues and cancers [144,145], targeting them might diminish normal tissue damage.”
BackgroundFRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody–Drug Conjugates
Lee, B.-C., Chalouni, C. M., Doll, S., Nalle, S. C., Darwish, M., Tsai, S. P., Kozak, K. R., Del-Rosario, G., Yu, S., Erickson, H. K., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00362 · Cited by 35
Self-citationAntibody-drug Conjugate Targets, Drugs, and Linkers
Teicher, B. A., & Morris, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220224110538 · Cited by 35
Dark force rising: Reawakening and targeting of fetal-like stem cells in colorectal cancer
Fey, S. K., Vaquero-Siguero, N., & Jackstadt, R. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114270 · Cited by 32
Marcucci, F., Caserta, C. A., Romeo, E. L., & Rumio, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00167 · Cited by 35
Petti, L., Rizzo, G. S., Rubbino, F., Elangovan, S., Colombo, P., Restelli, S., Piontini, A., Arena, V., Carvello, M., Romano, B., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01740-6 · Cited by 33
Impact of Cancer Stem Cells on Therapy Resistance in Gastric Cancer
Otaegi-Ugartemendia, M., Matheu, A., & Carrasco‐García, E. (2022) · Cancers · doi:10.3390/cancers14061457 · Cited by 34
Conti, S., Venturini, V., Cañellas-Socias, A., Cortina, C., Abenza, J. F., Attolini, C. S., Guerra, E. M., Xu, C. K., Li, J. H., Rossetti, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47227-2 · Cited by 31
WDR76 degrades RAS and suppresses cancer stem cell activation in colorectal cancer
Ro, E. J., Cho, Y., Jeong, W.-J., Park, J., Min, D. S., & Choi, K. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0403-x · Cited by 35
Wei, C., Su, D., Wang, J., Jian, W., & Zhang, D. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-017-0118-x · Cited by 32
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance
Wang, W., Lokman, N. A., Barry, S. C., Oehler, M. K., & Ricciardelli, C. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10239-x · Cited by 34
Targeting Cancer Stem Cells: Therapeutic and diagnostic strategies by the virtue of nanoparticles
Shrestha, S., Banstola, A., Jeong, J., Seo, J. H., & Yook, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.013 · Cited by 29
Buongervino, S. N., Lane, M. V., Garrigan, E., Zhelev, D. V., Dimitrov, D. S., & Bosse, K. R. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1034 · Cited by 34
Emerging Therapeutic Agents for Colorectal Cancer
Nalli, M., Puxeddu, M., Regina, G. L., Gianni, S., & Silvestri, R. (2021) · Molecules · doi:10.3390/molecules26247463 · Cited by 29
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?
de Pellegars-Malhortie, A., Lasorsa, L., Mazard, T., Granier, F., & Prévostel, C. (2024) · Pharmaceuticals · doi:10.3390/ph17070949 · Cited by 30
“The encouraging preclinical efficacy and safety findings supported their further evaluation in patients with gastrointestinal cancer [282,283].”
BackgroundWNT signaling in cancer: molecular mechanisms and potential therapies
Liang, J., Pan, Y., Yang, J., Zeng, D., & Li, J. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00327-x · Cited by 41
Geles, K. G., Gao, Y., Giannakou, A., Sridharan, L., Yamin, T.-T., Zhang, J., Karim, R., Bard, J., Piche‐Nicholas, N., Charati, M. B., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100279 · Cited by 30
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow
Becht, R., Kiełbowski, K., & Wasilewicz, M. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031456 · Cited by 31
“Few studies examined targeting Lgr5-positive cells in treating cancer and showed promising efficacy of antibody–drug conjugates against Lgr5-high gastrointestinal tumors [221,222].”
BackgroundFerhati, X., Jiménez‐Moreno, E., Hoyt, E. A., Salluce, G., Cabeza-Cabrerizo, M., Navo, C. D., Compañón, I., Akkapeddi, P., Matos, M. J., Salaverri, N., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07675 · Cited by 25
Martin, A. R., Ronco, C., Demange, L., & Benhida, R. (2016) · MedChemComm · doi:10.1039/c6md00432f · Cited by 30
Park, S., Kim, S. Y., Cho, J., Jung, D., Seo, D., Lee, J., Lee, S., Yun, S., Lee, H., Park, O., et al. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00340 · Cited by 26
Cancer Stem Cells in Soft-Tissue Sarcomas
Martínez-Delgado, P., Lacerenza, S., Obrador‐Hevia, A., López-Álvarez, M., Mondaza-Hernandez, J. L., Blanco‐Alcaina, E., Sánchez-Bustos, P., Hindi, N., Moura, D. S., & Martín‐Broto, J. (2020) · Cells · doi:10.3390/cells9061449 · Cited by 30
Lundberg, A. S., Geuijen, C. A. W., Hill, S., van Bueren, J. J. L., Fumagalli, A., de Kruif, J., Silverman, P. B., & Tabernero, J. M. (2025) · Cancers · doi:10.3390/cancers17101665 · Cited by 27
“At least three LGR5-targeting ADCs with different linkers, toxins, and drug-to-antibody ratios have been tested in preclinical models; however, no clinical trials on LGR5-directed ADCs have been reported to date [42–46].”
Azhdarinia, A., Voss, J., Ghosh, S. C., Simien, J., Vargas, S. H., Cui, J., Yu, W., Liu, Q., & Carmon, K. S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00275 · Cited by 24
Jha, R., Singh, M., Wu, Q., Gentillon, C., Preininger, M. K., & Xu, C. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.07.006 · Cited by 26
“…(Barker et al., 2007, 2010, 2012; Chai et al., 2012; de Visser et al., 2012; Jaks et al., 2008; Sato et al., 2009), and is overexpressed in cancer stem cells and several types of tumors (Barker et al., 2009; Junttila et al., 2015; McCla-nahan et al., 2006; Nakata et al., 2013; Tanese et al., 2008).”
BackgroundSelf-citationOlsen, C. E., Cheung, L. H., Weyergang, A., Berg, K., Vallera, D. A., Rosenblum, M. G., & Selbo, P. K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010068 · Cited by 23
“Such strategies may involve multimodality treatments including immunotoxins (IT) targeting e.g., CD133-expressing [9,10] or LGR5 + [11] CSCs. CD133 (prominin-1) is a pentaspan glycoprotein over-expressed on several types of CSCs and is an independent prognostic factor for clinical outcome in…”
Cell cycle heterogeneity and plasticity of colorectal cancer stem cells
Higa, T., & Nakayama, K. I. (2024) · Cancer Science · doi:10.1111/cas.16117 · Cited by 22
“34,35 Despite evidence suggesting the importance of Lgr5 + CSCs in CRC, it remains unclear whether therapeutic targeting of these cells can result in the eradication of CRC.”
BackgroundEssex, A., Pineda, J. J., Acharya, G., Xin, H., Evans, J., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., Perfito, N., et al. (2019) · eLife · doi:10.7554/elife.45426 · Cited by 23
“Moreover, recent studies have also reported CSC properties from cells with high expression of Wnt target genes, such as LGR5 (Dame et al., 2018; Junttila et al., 2015; Shimokawa et al., 2017).”
He, J., Han, J., Lin, K., Wang, J., Li, G., Li, X., & Gao, Y. H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.10.049 · Cited by 26
Vishnubalaji, R., Shaath, H., Al-Alwan, M. M., Abdelalim, E. M., & Alajez, N. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.10.007 · Cited by 23
G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions
High, P. C., & Carmon, K. S. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216191 · Cited by 21
Posey, T. A., Jacob, J., Parkhurst, A. N., Subramanian, S., Francisco, L. E., Liang, Z., & Carmon, K. S. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0415 · Cited by 22
Extracellular vesicles for developing targeted hearing loss therapy
Pan, X., Li, Y., Huang, P., Staecker, H., & He, M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.050 · Cited by 25
Cao, J., Li, C., Wei, X., Tu, M., Zhang, Y., Xu, F., & Xu, Y. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0694 · Cited by 20
“Most CSC-targeted therapeutic effects using ADCs (21, 42), Bite (bispecific T-cell engager; ref.”
BackgroundDiPrima, M., Wang, D., Tröster, A., Maric, D., Terrades-García, N., Ha, T., Kwak, H., Sánchez‐Martín, D., Kudlinzki, D., Schwalbe, H., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12576 · Cited by 19
“Most colorectal cancers contain Lgr5+ cells (Junttila et al., 2015; Shimokawa et al., Abbreviations 3-MA, 3-methyladenine; ATG, autophagy-related gene; CMS, consensus molecular subtype; CPTAC, Clinical Proteome Tumor Analysis Consortium; HUVEC, human umbilical vein endothelial cells; KD,…”
Background
Metadata
- Authors
- Junttila, M. R., Mao, W., Wang, X., Wang, B.-E., Pham, T., Flygare, J., Yu, S.-F., Yee, S., Goldenberg, D., Fields, C., Eastham-Anderson, J., Singh, M., Vij, R., Hongo, J.-A., Firestein, R., Schutten, M., Flagella, K., Polakis, P., & Polson, A. G.
- Affiliations
- Genentech (US)
- Research and Early Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
- Corresponding author
- Junttila, Melissa R.
- Singh, Mallika
- Firestein, Ron
- Flagella, Kelly
- Polson, Andrew G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-11-18
- Volume
- 7
- Issue
- 314
- Pages
- 314ra186-314ra186
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2174197315
- Cited by
- 182
- References
- 32
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 19 · 2023: 17 · 2022: 7 · 2021: 23 · 2020: 19 · 2019: 20 · 2018: 24 · 2017: 13 · 2016: 10 · 2015: 1
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech Inc.
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- Lgr5, antibody-drug conjugates, colon cancer, cancer stem cells, tissue stem cells, targeted cancer therapy, G protein-coupled receptors, genetically engineered mouse models, intestinal tumorigenesis, tumor growth inhibition, drug safety
- MeSH terms
- Animals, Immunotoxins, Antineoplastic Agents, Colonic Neoplasms, Dose-Response Relationship, Drug, Feasibility Studies, Female, Male, Mice, Inbred C57BL, Mice, Nude, Mice, Transgenic, Time Factors, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Rats, Sprague-Dawley, Genes, APC, Inhibitory Concentration 50, Xenograft Model Antitumor Assays, Receptors, G-Protein-Coupled, Cell Line, Tumor, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.